Ethics and Professionalism
In August 2013, the AMA adopted the World Medical Association's (WMA) Regulations in Times of Armed Conflict and Other Situations of Violence 2012 as formal AMA policy. The regulations address the duties of doctors working in armed conflict and other situations of violence as well as the obligations of governments, armed forces, and others in positions of power to protect health care personnel and allow them to fulfill their ethical duties to provide care to anyone in need.
The AMA has made the following submission to the Senate Inquiry into the Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013.
Many members have recently received what we un
This document provides guidance for medical practitioners on maintaining ethical relationships with industry including the pharmaceutical industry, medical device and technology industry, and other health care product suppliers, health care facilities, medical services such as pathology and radiology, and other health services such as pharmacy and physiotherapy.
Thank you for providing the Australian Medical
The AMA congratulates the Government on its efforts to bring forward a plan to protect and respect access to hospitals and medical care in Syria, which is under constant threat of disruption during the ongoing conflict there.
The Minister for Foreign Affairs, Bob Carr, said today that Australia would be seeking international support for this humanitarian goal.
According to the Minister’s statement, this plan would involve securing a commitment from all sides:
- Not to block medical personnel;
- Not to block access to doctors, hospitals, or emergency care; and
- Not to attack medical facilities.
AMA President, Dr Steve Hambleton, said that doctors have a duty to care for the sick and injured, even under threat, and regardless of the individual's creed, ethnic origin, nationality, or political affiliation.
The AMA supports the reauthorisation of the Medicines Australia Code of Conduct. The AMA acknowledges the move towards greater transparency of pharmaceutical sponsorship, through the reporting of aggregate payments.